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OutcomeAbstract Middle East Respiratory Syndrome (MERS) is a novel respiratory illness ﬁrstly reported
in Saudi Arabia in 2012. It is caused by a new corona virus, called MERS corona virus (MERS-
CoV). Most people who have MERS-CoV infection developed severe acute respiratory illness.
Aim of the work: This work is done to determine the clinical characteristics and the outcome of
intensive care unit (ICU) admitted patients with conﬁrmed MERS-CoV infection.
Patients and methods: This study included 32 laboratory conﬁrmed MERS corona virus infected
patients who were admitted into ICU. It included 20 (62.50%) males and 12 (37.50%) females. The
mean age was 43.99 ± 13.03 years. Diagnosis was done by real-time reverse transcription poly-
merase chain reaction (rRT-PCR) test for corona virus on throat swab, sputum, tracheal aspirate,
or bronchoalveolar lavage specimens. Clinical characteristics, co-morbidities and outcome were
reported for all subjects.
Results: The main symptoms among the included patients were: fever (96.87%), cough
(93.75%), dyspnea (90.62%), sore throat (75%), runny nose (75%), sputum (50%), headache
(43.75%), myalgia (40.62%), chest pain (37.50%), hemoptysis (37.50%), nausea and vomiting
(34.37%), abdominal pain (21.87%) and diarrhea (15.62%). The presence of abdominal symptoms
is signiﬁcantly (P< 0.05) associated with bad prognosis. Out of the included 32 patients, 18
patients (56.25%) survived and 14 patients (43.75%) expired. There was a statistically signiﬁcant
difference in the duration of symptoms before hospitalization, mechanical ventilation and ICU
and total hospital stay between the expired group and survivors (P< 0.01). Current smoking
and smoking severity were statistically signiﬁcantly (P< 0.01) higher in the expired group com-
pared to survivors. Also, there was a statistically (P< 0.05) signiﬁcant positive correlation between
mortality and smoking severity (r= 0.640). Most of the expired patients presented with bilateral
pulmonary inﬁltrates or unilateral inﬁltrates, but most of the survivors presented with normalrculosis.
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highly signiﬁcant (P< 0.01). There were statistically highly signiﬁcant (P< 0.01) differences in the
mean values of APACHE II score (21.11 ± 3.70 vs 24.21 ± 3.82), SOFA score (5.83 ± 2.64 vs
8.85 ± 2.17) and CPIS (7.55 ± 1.14 vs 8.64 ± 1.39) between the expired group and survivors
respectively. Also, there was a statistically signiﬁcant decrease in PH, PaO2, O2 saturation and
HCO3 (P< 0.05) among the expired group in comparison with the survivors, but no statistical dif-
ference regarding PaCO2 (P> 0.05). There was a statistically signiﬁcant positive correlation
between mortality and old age (r= 0.633), obesity (r= 0.712), diabetes mellitus (r= 0.685), renal
failure (r= 0.705), chronic heart diseases (0.591), COPD (r= 0.523), malignancy (r= 0.692), kid-
ney transplantation (r= 0.644) and liver cirrhosis (r= 0.525) (P< 0.05). There was a statistically
(P< 0.05) positive correlation between the number of associated co-morbidities and mortality
(r= 0.735).
Conclusions: Most MERS corona patients present with fever, cough, dyspnea, sore throat, runny
nose and sputum. The presence of abdominal symptoms may indicate bad prognosis. Prolonged
duration of symptoms before patients’ hospitalization, prolonged duration of mechanical ventila-
tion and hospital stay, bilateral radiological pulmonary inﬁltrates, and hypoxemic respiratory fail-
ure were found to be strong predictors of mortality in such patients. Also, old age, current smoking,
smoking severity, presence of associated co-morbidities like obesity, diabetes mellitus, chronic heart
diseases, COPD, malignancy, renal failure, renal transplantation and liver cirrhosis are associated
with a poor outcome of ICU admitted MERS corona virus infected patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Middle East Respiratory Syndrome (MERS) is a new viral res-
piratory infection caused by a newly discovered corona virus,
speciﬁcally, called Middle East Respiratory Syndrome Corona
virus (MERS-CoV). In September 2012, the World Health
Organization reported the ﬁrst case of pneumonia caused by
MERS-CoV in Saudi Arabia. All cases of MERS have been
linked to countries in and near the Arabian Peninsula. This
virus has spread from ill people to others through close con-
tact, such as caring for or living with an infected person. Also,
contact with the camels may be a potential source. However,
there is no evidence of sustained spread in community settings.
Most MERS patients developed a severe acute respiratory ill-
ness [1,2].
Aim of the work
This work is done to determine the clinical characteristics and
the outcome of ICU admitted patients with conﬁrmed MERS-
CoV infection.
Patients and methods
This study included 32 laboratory conﬁrmed MERS corona
virus patients who were admitted into ICU. Consent was taken
from the patients or their relatives.
All studied cases were subjected to:
(1) Full medical history.
(2) Thorough clinical examination.
(3) Calculation of body mass index (BMI): a BMI of >30 is
considered obese according to WHO [3].
(4) Routine laboratory investigations (complete blood count,
kidney and liver functions, and blood sugar testing).(5) Radiological assessment: chest X-ray (posteroanterior
and lateral views) and computed tomography (CT).
(6) Arterial blood gases, including; PH, PaO2, SaO2, PaCO2
and HCO3.
(7) Acute Physiology and Chronic Health Evaluation II
(APACHE II) score, the Sequential Organ Failure
Assessment score (SOFA) and the Clinical Pulmonary
Infection Score (CPIS).
(8) Throat swab (Eurotubo, Deltalab, 08191 Rubı´, Barce-
lona, Spain), sputum, tracheal aspirate or bronchoalve-
olar lavage specimens were taken and stored at 28 C,
and transported within 72 h to the reference laborato-
ries, where they were subjected to real-time reverse-tran
scriptase–polymerase-chain-reaction (rRT-PCR) assays
to test for MERS-CoV (Altona Diagnostics GmbH,
22767 Hamburg, Germany). For all patients, the results
of rRT-PCR tests were conﬁrmed by measuring cycle-
threshold values for viral load [4].
Statistical analysis
The statistical analysis was performed with the Statistical
Package for the Social Sciences, version 16 for Windows (SPSS
Inc., Chicago, IL, USA). Chi-square test was used to measure
association. Pearson’s correlation test was used to measure
correlation. Values of P< 0.05 were considered statistically
signiﬁcant.
Results
In this study, there were 20 (62.50%) males and 12 (37.50%)
females. The mean age was 43.99 ± 13.03 years.
The main symptoms among the included patients were:
fever (96.87%), cough (93.75%), dyspnea (90.62%), sore
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(43.75%), myalgia (40.62%), chest pain (37.50%), hemoptysis
(37.50%), nausea and vomiting (34.37%), abdominal pain
(28.12%), abdominal pain (21.87%) and diarrhea (15.62%).
The mean duration of symptoms before seeking medical advice
was 5.30 ± 3.25 days (Table 1).
The chest radiological ﬁndings among the included patients
were as follows: 8 (25%) normal chest radiology, 5 (15.63%)
increased bronchovascular markings, 7 (21.87%) unilateral
inﬁltrates, and 12 (37.50%) diffuse bilateral inﬁltrates. Pneu-
mothorax occurred in 5 (15.63%) ventilated patients, for 3
of them it was unilateral and for other 2 patients bilateral
(Table 1).
Regarding the ABGs ﬁndings in our study: mean PH: 7.26
± 0.33, mean PaO2: 64.04 ± 20.50 mmHg, mean O2 satura-
tion: 83.92 ± 17.45, mean PaCO2: 38.75 ± 4.17 mmHg, and
mean HCO3 19.44 ± 8.5 meq/L (Table 1).Table 1 Characteristics of the patients included in this study.
Parameters No (%)
Sex
Males 20 (62.50%)
Females 12 (37.50%)
Age (years) 43.99 ± 13.03
Symptoms
Fever 31 (96.87%)
Cough 30 (93.75%)
Dyspnea 29 (90.62%)
Sore throat 24 (75%)
Runny nose 24 (75%)
Sputum 16 (50%)
Headache 14 (43.75%)
Myalgia 13 (40.62)
Chest pain 12 (37.50)
Hemoptysis 12 (37.50%)
Nausea and vomiting 11 (34.37%)
Abdominal pain 7 (21.87)
Diarrhea 5 (15.62)
Radiology
Normal chest radiology 8 (25%)
Increased bronchovascular markings 5 (15.63%)
Unilateral inﬁltrates 7 (21.87%)
Diﬀuse bilateral inﬁltrates 12 (37.50%)
Pneumothorax 5 (15.63%)
ABGs
PH 7.26 ± 0.33
PaO2 (mmHg) 64.04 ± 20.50
O2 saturation 83.92 ± 17.45
PaCO2 (mmHg) 38.75 ± 4.17
HCO3 (meq/L) 19.44 ± 8.5
Scores
APACHE II 22.46 ± 4.01
SOFA score 7.15 ± 2.85
CPIS 8.03 ± 1.35
Duration
Symptoms before hospitalization 5.30 ± 3.25
Mechanical ventilation 6.21 ± 3.76
ICU stay 11.32 ± 4.50
Total length of hospital stay 15 ± 3.60The mean APACHE II score was 22.46 ± 4.01, the mean
SOFA score was 7.15 ± 2.85 and mean CPIS was 8.03
± 1.35 (Table 1).
Regarding the presence of co-morbidity, 21 (65.62%)
patients out of the included 32 patients were associated with
one or more co-morbidities and 11 (34.38%) patients were
without co-morbidity (Table 2).
All patients were admitted in ICU and a mean duration of
ICU stay was 11.32 ± 4.50 days. Regarding mechanical venti-
lation need, there were 23 (71.87%) ventilated patients and 9
(28.13%) patients without mechanical ventilation. For venti-
lated patients the mean duration of mechanical ventilation
was 6.21 ± 3.76 days. The mean total hospital stay was 15
± 3.6 days (Table 1).
According to the outcome of 32 patients included in this
study, there were two groups:
(1) The survivor group that included 18 patients (56.25%)
with a mean age of 37.25 ± 15.50 years.
(2) The expired group that included 14 patients (43.75%)
with a mean age of 50.47 ± 13.80 years.
There was a highly statistically signiﬁcant (P< 0.01) differ-
ence between the expired group and the survivors regarding
the duration of mechanical ventilation (expired: 9.64 ± 2.46,
survivors: 3.55 ± 2.00), ICU stay (expired: 13.98 ± 3.50, sur-
vivors: 8.66 ± 2.40) and total hospital stay (expired: 17.50
± 2.92, survivors: 13.06 ± 2.81) (Table 2).
In this study, in spite of a statistically signiﬁcant (P< 0.05)
increase in occurrence of corona virus infection among males
in comparison with females (62.50% males and 37.50%
females), there was no statistically signiﬁcant difference
(P> 0.05) in the mortality among them (45% among males
and 41.67% among females) (P> 0.05) (Table 2).
Current smoking and smoking severity were statistically
signiﬁcantly (P< 0.01) higher in the expired group compared
to the survivors. Non smoking and ex smoking were statisti-
cally signiﬁcantly (P< 0.01) higher among survivors in com-
parison with the expired group. Also, there was a statistically
(P< 0.05) signiﬁcant positive correlation between mortality
and smoking severity (r= 0.640) (Table 2).
In this study, there were no statistically signiﬁcant differ-
ences between the expired and survivors groups as regards
fever, cough, dyspnea, runny nose, sore throat, chest pain,
hemoptysis, myalgia or headache (P> 0.05), but there was a
statistically signiﬁcant increase in frequency of nausea, vomit-
ing and diarrhea among the expired group than that among
the survivors (P< 0.05). Also, there was a statistically signif-
icant increase in the duration of the symptoms before the hos-
pitalization among the expired group than that among the
survivors (P< 0.05) (Table 2). There was a statistically signif-
icant (P< 0.05) positive correlation (r= 0.681) between mor-
tality and prolonged duration of illness before hospitalization.
Our study showed that most of the expired patients pre-
sented with bilateral pulmonary inﬁltrates or unilateral inﬁl-
trates, but most of the survivors presented with normal
radiology or increased bronchovascular markings, and this dif-
ference in the results was statistically highly signiﬁcant
(P< 0.01) (Table 2).
There were statistically highly signiﬁcant (P< 0.01) differ-
ences in the mean values of APACHE II score (21.11 ± 3.70 vs
24.21 ± 3.82), SOFA score (5.83 ± 2.64 vs 8.85 ± 2.17) and
Table 3 Correlation between the mortality and the co-
morbidities in the studied patients.
Co-morbidities Pearson’s correlation P-value
Age 0.633 <0.05
Smoking severity 0.640 <0.05
Obesity 0.712 <0.05
DM 0.685 <0.05
Chronic heart diseases 0.591 <0.05
COPD 0.523 <0.05
Renal failure 0.705 <0.05
Malignancy 0.692 <0.05
Kidney transplantation 0.644 <0.05
Liver cirrhosis 0.525 <0.05
Table 2 Comparison between survivor and expired groups.
Parameters Survivors (N= 18) Expired (N= 14) P value
Age (Mean ± SD) 37.25 ± 15.50 50.47 ± 13.80 P< 0.05
Sex
Males (No = 20) 11 (55%) 9 (45%)
Females (No = 12) 7 (58.33%) 5 (41.67%)
P value P> 0.05 P> 0.05
Smoking
Current 4 (22.22%) 10 (71.42%) P< 0.01
Ex smoker 5 (27.78%) 2 (14.29%) P< 0.01
Non smoker 9 (50%) 2 (14.29%) P< 0.01
Radiology
Normal (No = 8) 6 (33.33%) 2 (14.29%) P< 0.01
BVMs (No = 5) 4 (22.22%) 1 (7.14%) P< 0.01
Unilateral inﬁltrates (No = 7) 6 (33.33%) 1 (7.14%) P< 0.01
Bilateral inﬁltrates (No = 12) 2 (11.12%) 10 (71.43%) P< 0.01
ABGs
PH 7.32 ± 0.05 7.20 ± 0.031 P< 0.05
PaO2 (mmHg) 75.81 ± 18.60 52.28 ± 14.60 P< 0.05
PaCO2 (mmHg) 38.20 ± 5.70 39.30 ± 5.37 P> 0.05
HCO3 (meq/L) 24.11 ± 3.01 14.77 ± 5.50 P< 0.05
O2 saturation (%) 92.70 ± 8.69 75.14 ± 10.40 P< 0.05
APACHE II 21.11 ± 3.70 24.21 ± 3.82 P< 0.05
SOFA 5.83 ± 2.64 8.85 ± 2.17 P< 0.05
CPIS 7.55 ± 1.14 8.64 ± 1.39 P< 0.05
No co-morbidities 9 2 P< 0.01
Co-morbidities
Obesity 2 8 P< 0.01
DM 3 10 P< 0.01
Chronic heart diseases 1 7 P< 0.01
COPD 2 4 P< 0.01
Renal failure 1 6 P< 0.01
Malignancy 0 3 P< 0.01
Kidney transplantation 0 1 P< 0.01
Liver cirrhosis 0 1 P< 0.01
Duration
Duration of symptoms 4.07 ± 2.50 6.54 ± 3.01 P< 0.05
Mechanical ventilation 3.55 ± 2.00 9.64 ± 2.46 P< 0.01
ICU stay 8.66 ± 2.40 13.98 ± 3.50 P< 0.01
Total length of hospital stay 13.06 ± 2.81 17.50 ± 2.92 P< 0.01
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and survivors respectively (Table 2).
This study found a statistically signiﬁcant decrease in PH,
PaO2, O2 saturation and HCO3 (P< 0.05) among the expired
group in comparison with the survivors, but no statistical dif-
ference regarding PaCO2 (P> 0.05) (Table 2).
As regards the correlation between mortality and speciﬁc
co-morbidities, there was a statistically signiﬁcant positive cor-
relation between mortality and old age (r= 0.633, smoking
(r= 0.640), obesity (r= 0.712), diabetes mellitus
(r= 0.685), renal failure (r= 0.705), chronic heart diseases
(0.591), COPD (r= 0.523), malignancy (r= 0.692), kidney
transplantation (r= 0.644) and liver cirrhosis (r= 0.525)
(P< 0.05), (Table 3). There was a statistical (P< 0.05) posi-
tive correlation between the number of associated co-
morbidities and mortality (r= 0.735).
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In this study, there were 20 (62.50%) males and 12 (37.50%)
females. This sex distribution showed a signiﬁcant (P< 0.05)
increase in the occurrence of corona virus infection among
males, but there was no statistically signiﬁcant difference
(P> 0.05) in the mortality among them (45% among males
and 41.67% among females). Our results agree with other
workers’ results [6,7]. The increased occurrence of corona virus
infection among males can be explained by excess movement
of the males through community with more exposure to the
infected patients.
In this study, there was high mortality (14 patients
(43.75%) out of 32) among corona virus infected patients
and there was a statistically signiﬁcant (P< 0.05) increase in
mortality in middle and old aged patients in comparison to
young patients (mean ages: 50.47 ± 13.80 among the expired
group vs 37.25 ± 15.50 among survivors). Also, there was a
statistically signiﬁcant (P< 0.05) positive correlation
(r= 0.633) between age and mortality. Other researchers
found similar results [5–14]. This high mortality rate among
corona virus infected old patients is explained by the high vir-
ulence of the new virus in the absence of previous immunity
and already compromised immune system among old peoples.
The most common symptoms among the included patients
were: fever (96.87%), cough (93.75%), dyspnea (90.62%), sore
throat (75%), runny nose (75%), and sputum (50%). There
were statistically signiﬁcant differences between the expired
and survivors groups regards fever, cough, dyspnea, runny
nose, sore throat, chest pain, hemoptysis, myalgia or headache
(P> 0.05), but the frequency of nausea, vomiting and diar-
rhea were statistically signiﬁcant higher among the expired
group in comparison to the survivors (P< 0.05). These ﬁnd-
ings could be explained by the fact that the presence of nausea,
vomiting and diarrhoea leads to dehydration (due to poor oral
intake and ﬂuid loss) with its detrimental effects. The duration
of symptoms before hospitalization, ICU stay, mechanical
ventilation and hospital stay in our studied patients were sta-
tistically signiﬁcantly prolonged in the expired group com-
pared to the survivors. Also, there was a statistically
signiﬁcant (P< 0.05) positive correlation (r= 0.681) between
mortality and prolonged duration of illness before hospitaliza-
tion. Other investigators found similar results [5–8]. These
results can be explained by a delay in diagnosis and manage-
ment of corona infected patients’ result in deterioration in their
health status with more need for ICU admission, mechanical
ventilation, increased total hospital stay and poor outcome.
Also, Al-Tawﬁq et al. [9] found that corona patients in com-
parison with controls were more likely to be admitted to the
intensive care unit (53% vs 20%; OR, 4.65; P= .025) and to
have a high mortality rate (76% vs 15%; OR, 18.96;
P< 0.001).
The chest radiological ﬁndings among the included patients
were as follows: 8 (25%) normal chest radiology, 5 (15.63%)
increased bronchovascular markings, 7 (21.87%) unilateral
inﬁltrates, and 12 (37.50%) diffuse bilateral inﬁltrates. Pneu-
mothorax occurred in 5 (15.63%) ventilated patients, for 3
of them it was unilateral and for other 2 patients bilateral.
Most of the expired patients presented with bilateral pul-
monary inﬁltrates or unilateral inﬁltrates, but most of the sur-
vivors presented with normal radiology or increasedbronchovascular markings, and this difference in the results
was statistically highly signiﬁcant (P< 0.01). Our ﬁndings
agree with other investigators who detected similar results
[7–9,15]. These extensive radiological shadows are denoting
extensive lung pathology with its detrimental effects on pul-
monary gas exchange and general condition of the patients
with more need for mechanical ventilation and are associated
with bad prognosis.
This study found a statistically signiﬁcant decrease in PH,
PaO2, O2 saturation and HCO3 (P< 0.05) among the expired
group in comparison to the survivors, but no statistical differ-
ence regarding PaCO2 (P> 0.05). Our results are in accor-
dance with that of Reyes et al. [16] who reported that one of
the independent variables that were associated with high mor-
tality was hypoxemia among SARS patients caused by a cor-
ona virus.
Current smoking and smoking severity were statistically
signiﬁcantly (P< 0.01) higher in the expired group compared
to the survivors. Non smoking and ex smoking were statisti-
cally signiﬁcantly (P< 0.01) higher among the survivors in
comparison with the expired group. Also, there was statisti-
cally (P< 0.05) signiﬁcant positive correlation between mor-
tality and smoking severity (r= 0.640). These results are in
agreement with previous data that showed that smoking is a
major determinant of morbidity and mortality in respiratory
tract infection, especially in populations that smoke heavily
[6–8]. Cigarette smoking is associated with a variety of alter-
ations in cellular and humoral immune system functions.
These alterations include a decreased level of circulating
immunoglobulins, a depression of antibody responses to cer-
tain antigens, a decrease in CD4+ lymphocyte counts, an
increase in CD8+ lymphocyte counts, depressed phagocyte
activity and a decreased release of pro inﬂammatory cytokines.
[17]. Smoking increases CD8+ lymphocytes in the cell medi-
ated system and suppresses the host defense against infections
[18].
There was a statistically signiﬁcant (P< 0.05) positive cor-
relation between mortality and obesity (r= 0.712). Several
studies indicate that morbid obesity may be an independent
risk factor for complications and mortality from MERS cor-
ona virus infection [6–9]. There are some explanations for
these results. Obesity can impede pulmonary function (reduced
functional residual capacity and expiratory volume). A subse-
quent ventilation–perfusion abnormality may decrease ventila-
tory reserve and predispose the obese to respiratory failure
after even mild pulmonary challenges [19,20]. Obstructive sleep
apnea is present in 40% of obese persons and is associated with
systemic hypertension, pulmonary hypertension, and cor pul-
monale [21,22]. Obese persons are at an increased risk of devel-
oping pulmonary emboli and aspiration pneumonia. Morbid
obesity is associated with complications in the intensive care
unit including prolonged stay, prolonged ventilation and death
[23,24]. In addition to its effects on pulmonary function, obe-
sity is frequently, but not always associated with diabetes,
hypertension, hyperlipidemia, cardiovascular disease and high
overall mortality [20].
Our work found a statistically signiﬁcant positive correla-
tion between mortality and diabetes mellitus (r= 0.685), renal
failure (r= 0.705), chronic heart diseases (0.591), COPD
(r= 0.523), malignancy (r= 0.692), kidney transplantation
(r= 0.644) and liver cirrhosis (r= 0.525) (P< 0.05),
(Table 3). There was a statistically (P< 0.05) positive correla-
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mortality (r= 0.735). Our results are in accordance with other
workers’ results [6–14]. Also, Arabi et al. [25] concluded that
people with DM, renal failure, and chronic lung disease and
immuno-compromised persons are considered to be at a high
risk of severe disease from MERS CoV infection. Also, our
results are in agreement with previous data showing that
patients who are immuno-compromised as a result of chronic
diseases, malignancy, receiving treatment related to solid
organ transplants and DM are at a high risk of respiratory
tract infection-related complications including mortality
[26,27]. Immuno-compromised patients have an increased
attention because of the documentation of prolonged viral
shedding in critically ill patients, with the subsequent emer-
gence of resistance to neuraminidase inhibitor drugs [28].
Renal failure population has many factors such as overwhelm-
ing uremia, neutrophil dysfunction, malnutrition, trace ele-
ments’ deﬁciencies, iron overload, impaired glucose
metabolism, and hyperparathyroidism, and the use of
immunosuppressive drugs to treat and control underlying dis-
eases leads to increased morbidity and mortality of infection
[29]. Casqueiro et al. [30] concluded that the infectious diseases
are more frequent and/or serious in patients with DM, which
potentially increases their morbidity and mortality due to
many factors as a deﬁciency of the C4 component in DM, this
reduction of C4 is probably associated with polymorphonu-
clear dysfunction and reduced cytokine response decrease
secretion of inﬂammatory cytokines as interleukin-1 (IL-1)
and IL-6 decreased mobilization of polymorphonuclear leuko-
cytes, chemotaxis and phagocytic activity. CD4 T-lymphocytes
and their response to antigens are impaired.
Conclusions
Most MERS corona patients present with fever, cough, dysp-
nea, sore throat, runny nose and sputum. The presence of
abdominal symptoms may indicate bad prognosis. Prolonged
duration of symptoms before patients’ hospitalization, pro-
longed duration of mechanical ventilation and hospital stay,
bilateral radiological pulmonary inﬁltrates, and hypoxemic
respiratory failure were found to be strong predictors of mor-
tality in such patients. Also, old age, current smoking, smoking
severity, presence of associated co-morbidities like obesity, dia-
betes mellitus, chronic heart diseases, COPD, malignancy,
renal failure, renal transplantation and liver cirrhosis associ-
ated with a poor outcome of ICU admitted MERS corona
virus infected patients.
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